TRANSCEND NHL 001 试验中 lisocabtagene maraleucel 治疗患者的细胞因子释放综合征与神经事件管理成本
该研究基于 TRANSCEND NHL 001 试验数据,回顾性分析接受 lisocabtagene maraleucel 治疗的复发/难治性大 B 细胞淋巴瘤患者中细胞因子释放综合征(CRS)和神经事件(NE)的管理成本。
要点
- CRS/NE 总体发生率为 47.4%,其中 77.2% 为 ≤2 级。
- ≥3 级 CRS/NE 患者(22.8%)的医疗资源利用和成本显著更高。
- 成本主要来自设施费用,包括 ICU 和其他住院时长。
核心结论
- 严重 CRS/NE 发生率低的 CAR-T 疗法可能降低患者管理相关的医疗资源利用和成本。
研究设计与样本
- 基于 TRANSCEND NHL 001 关键试验的回顾性分析,纳入截至 2019 年 4 月接受 lisocabtagene maraleucel 治疗的 268 例复发/难治性大 B 细胞淋巴瘤患者。
- 从医疗系统角度,基于试验观察到的医疗资源利用和公开数据库及已发表文献的成本估算,分析 CRS/NE 管理成本。
主要发现
- 268 例接受治疗患者中,127 例(47.4%)发生任何级别 CRS 和/或 NE,其中 77.2% 为 ≤2 级。
- 成本主要驱动因素为设施费用,包括 ICU 和其他住院时长。
- ≥3 级不良事件患者(22.8%)的医疗资源利用和成本显著更高。
临床怎么用
- 临床中应关注 CRS/NE 的严重程度分级,≥3 级事件与显著更高的医疗资源利用和成本相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell therapies have demonstrated high response rates in patients with relapsed/refractory large B-cell lymphoma (LBCL); however, these therapies are associated with 2 CAR T cell-specific potentially severe adverse events (AEs): cytokine release syndrome (CRS) and neurological events (NEs). This study estimated the management costs associated with CRS/NEs among patients with relapsed/refractory LBCL using data from the pivotal TRANSCEND NHL 001 trial of lisocabtagene maraleucel, an investigational CD19-directed defined composition CAR T-cell product with a 4-1BB costimulation domain administered at equal target doses of CD8+ and CD4+ CAR+ T cells. This retrospective analysis of patients from TRANSCEND with prospectively identified CRS and/or NE episodes examined relevant trial-observed health care resource utilization (HCRU) associated with toxicity management based on the severity of the event from the health care system perspective. Cost estimates for this analysis were taken from publicly available databases and published literature. Of 268 treated patients as of April 2019, 127 (47.4%) experienced all-grade CRS and/or NEs, which were predominantly grade ≤2 (77.2%). Median total AE management costs ranged from $1930 (grade 1 NE) to $177 343 (concurrent grade ≥3 CRS and NE). Key drivers of cost were facility expenses, including intensive care unit and other inpatient hospitalization lengths of stay. HCRU and costs were significantly greater among patients with grade ≥3 AEs (22.8%). Therefore, CAR T-cell therapies with a low incidence of severe CRS/NEs will likely reduce HCRU and costs associated with managing patients receiving CAR T-cell therapy. This clinical trial was registered at www.clinicaltrials.gov as #NCT02631044.
引用
- Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021. PMID: 33720336. doi:10.1182/bloodadvances.2020003531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。